Dr. Mitchell Haut, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1455 Harrison Ave Nw, Ste 105
Canton, OH 44708
Who else practices at this address →
Stark County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 174
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Icahn School of Medicine at Mount Sinai
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Hematology & Oncology Physician primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Mercy Medical Center Canton, OH
- Aultman Hospital Canton, OH
- Union Hospital Dover, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 174
- Services billed
- 590
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 266 | 119 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 107 | 48 |
| Established patient office or other outpatient visit, 30-39 minutes | 89 | 58 |
| New patient office or other outpatient visit, 60-74 minutes | 32 | 32 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Canton, OH | 74 |
| Prochlorperazine Maleate Other prescribers in Canton, OH | 41 |
| Prednisone Other prescribers in Canton, OH | 21 |
| Abiraterone Acetate | 19 |
| Dexamethasone Other prescribers in Canton, OH | 16 |
| Acyclovir Other prescribers in Canton, OH | 15 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Canton, OH | 14 |
| Anastrozole Other prescribers in Canton, OH | 13 |
| Triamcinolone Acetonide Other prescribers in Canton, OH | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 6 companies. The companies reported $169,406 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative…
Merck Sharp & Dohme LLC - A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Daiichi Sankyo Inc. · Recruiting · NCT06203210 - An observational,prospective,multicenter study of non small cell lung cancer patients in the US receiving standard of care and initiating an approved therapy with risk of pneumonitis ILD
AstraZeneca UK Limited - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation - A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sanofi US Services Inc. · Completed · NCT04458831 - RealMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND)
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.